ACM
RCUS icon

AlphaCrest Capital Management’s Arcus Biosciences RCUS Stock Holding History

AlphaCrest Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,523
Closed -$929K – 897
2022
Q3 		$929K Sell
35,523
-90,711
-72% -$2.4M 0.06% 663
2022
Q2 		$3.2M Buy
+126,234
New +$3.09M 0.15% 153
2021
Q1 		– Sell
-16,200
Closed -$421K – 1283
2020
Q4 		$421K Buy
+16,200
New +$392K 0.04% 750

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

AlphaCrest Capital Management's RCUS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 35,523 shares — an estimated $929K sold.

AlphaCrest Capital Management first reported a position in RCUS in Q4 2020 and held it in 3 quarters. The position peaked at $3.2M in Q2 2022. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 35,523 Arcus Biosciences shares in Q4 2022, an estimated $929K.
  • AlphaCrest Capital Management first reported a position in Arcus Biosciences in Q4 2020 and held it in 3 quarters.
  • AlphaCrest Capital Management's Arcus Biosciences position peaked at $3.2M in Q2 2022.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.